Products
Cemavafusp Biosimilar Toxin–scFv Fusion Protein (PD-L1) for Research
Cat No.: GMP-Bios-INN-1126
Anti-PDL1/CD274 therapeutic antibody (Pre-made Cemavafusp biosimilar,Fusion Protein (Toxin fused to an scFv)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cemavafusp (development code MT-6402) is a fusion protein combining a Shiga-like toxin 1 subunit A1 with an antibody fragment targeting PD-L1 (CD274). It is developed by Molecular Templates for advanced solid tumors. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1126-1mg | 1mg | 3090 |
| GMP-Bios-INN-1126-10mg | 10mg | |
| GMP-Bios-INN-1126-100mg | 100mg | |
| GMP-Bios-INN-1126-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Cemavafusp biosimilar, Fusion Protein (Toxin fused to an scFv) targeting PDL1/CD274: Recombinant therapeutic protein targeting PD-L1/CD274/Programmed cell death 1 ligand 1/PDCD1 ligand 1 |
| INN Name | Cemavafusp |
| Target | PDL1/CD274 |
| Format | Fusion Protein (Toxin fused to an scFv) |
| Derivation | na |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | TBC |
| Conditions Approved | na |
| Conditions Active | Head and neck cancer;Non-small cell lung cancer;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
